Chimerix, Inc. (NASDAQ:CMRX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders. |
On June 28, 2017, Chimerix, Inc. (the
Company) held its 2017 Annual Meeting
of Stockholders (the Annual Meeting).
As of May 1, 2017, the record date for the Annual Meeting,
46,651,793 shares of common stock were outstanding and entitled
to vote at the Annual Meeting. At the Annual Meeting, 37,700,899
shares of common stock were present in person or represented by
proxy for the three proposals summarized below.
Proposal 1: Election of directors
The Companys stockholders elected the two persons listed below as
Class I directors, each to serve until the Companys 2020 Annual
Meeting of Stockholders and until their successors are duly
elected and qualified. The final voting results are as follows:
| Votes For | Votes Withheld | Broker Non-Votes | |
| M. Michelle Berrey, M.D., M.P.H. | 29,880,415 | 168,229 | 7,652,255 |
| Ronald C. Renaud, Jr. | 23,642,443 | 6,406,201 | 7,652,255 |
Proposal 2: Ratification of the selection of independent
registered public accounting firm
The Companys stockholders ratified the selection by the Audit
Committee of Ernst Young LLP as the Companys independent
registered public accounting firm for the fiscal year ending
December 31, 2017. The final voting results are as follows:
| Votes For | 30,366,207 |
| Votes Against | 7,318,893 |
| Abstentions | 15,799 |
| Broker Non-Votes |
Proposal 3: Approval, on a non-binding, advisory basis,
of the compensation of the Companys named executive
officers
The Companys stockholders approved, on a non-binding, advisory
basis, the compensation of the Companys named executive officers.
The final voting results are as follows:
| Votes For | 29,813,821 |
| Votes Against | 204,057 |
| Abstentions | 30,766 |
| Broker Non-Votes | 7,652,255 |
About Chimerix, Inc. (NASDAQ:CMRX)
Chimerix, Inc. (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against over five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir is marketed under the brand name Viread. The Company has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus.
